Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14960632 | 0.79 | PTGS1 (0.67) | PTGS1PTGS2 | |
| SCHEMBL5806458 | 0.78 | PTGS1 (0.55) | PTGS1PTGS2 | |
| SCHEMBL12320185 | 0.76 | PTGS1 (0.68) | PTGS1PTGS2 | |
| SCHEMBL16235233 | 0.76 | GAA (0.56) | PTGS2 | |
| SCHEMBL6120121 | 0.75 | PTGS1 (0.69) | PTGS1PTGS2 | |
| SCHEMBL14627251 | 0.75 | PTGS1 (0.53) | PTGS1PTGS2 | |
| SCHEMBL12277328 | 0.75 | PTGS1 (0.53) | PTGS1PTGS2 | |
| SCHEMBL521538 | 0.74 | PTGS1 (0.60) | PTGS1PTGS2 | |
| SCHEMBL10141341 | 0.74 | — | — | |
| SCHEMBL6012692 | 0.74 | PTGS1 (0.55) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | PTGS1 1453/4885PTGS2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.